D, Persesus Strategies. Founder, Freedom Now. International lawyer for Aung San Suu Kyi. Jeff George — Global Head, Sandoz. Member of Exec Committee, Novartis. Dave Goldberg — CEO, SurveyMonkey. Tom Goldstein -- Partner, Goldstein & Howe. Fmr Partner and head of Supreme Court practice, Akin Gump. Has argu

research. She launched marketing and outreach programs to convey Mount Sinai’s research capabilities. These efforts attracted ongoing contracts from Novartis, Smith Kline Beecham, Amgen and Pfizer and other pharmaceutical and biotech companies. She facilitated over $18 million in grant funding, increased c

arch capabilities. e Attracted ongoing contracts and right of first refusal in phase III clinical trials (with appropriate patient populations) from Novartis, Smith Kline Beecham, Amgen and Pfizer and other pharmaceutical and biotech companies. e Grew research revenue by increasing clinical trials by 40%

hen for "insights" about the Trump administration. AT&T's admission came after a lawyer for porn star Stormy Daniels claimed the company, drug giant Novartis and a Russian oligarch had all made payments to Cohen's shell company. HOUSE_OVERSIGHT_016218 --- PAGE BREAK --- Daniels' lawyer, Michael Avenatti

ersesus Strategies. Founder, Freedom Now. International lawyer for Aung San Suu Kyi. *Jeff George*iz% Global Head, Sandoz. Member of Exec Committee, Novartis. *Dave Goldberg*1iz% CEO, SurveyMonkey. *Tom Goldstein*-- Partner, Goldstein & Howe. Fmr Partner and head of Supreme Court practice, Akin Gump. Has

Persesus Strategies. Founder, Freedom Now. International lawyer for Aung San Suu Kyi. *Jeff George*— Global Head, Sandoz. Member of Exec Committee, Novartis. *Dave Goldberg*— CEO, SurveyMonkey. *Tom Goldstein*-- Partner, Goldstein & Howe. Fmr Partner and head of Supreme Court practice, Akin Gump. Has arg

bserver), Sirna Therapeutics (NASDAQ: RNAI, acquired by Merck in 2006 for $1.1 billion), where he served as Chairman; Oriel Therapeutics (acquired by Novartis in 2010), where he served as Executive Chairman, and Pearl Therapeutics (acquired by AstraZeneca in 2012). Prior to joining Sprout, Jim was Chief Sci

Marley Natural, Irisa, Goodship, Grail, and Dutchy. TLRY has been active on the M&A front, with previously announced acquisitions / partnerships with Novartis, Authentic Brands and AB-Inbev, among others. Most recently, the company announced a C$419 mm acquisition of Manitoba Harvest, the global leader in h

ast year on foreign ownership in its stock market.Novartis (NVS) has begun clinical trials of an experiment

of the drugmaker's cholesterol treatment Crestor. Novartis (NVS) and Mylan (MYL) are among the companies pre